Sterling Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Sterling Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-12,373	Closed	-$220K	–	990
2014 Q4	$220K	Sell	12,373 -39,737	-76%	-$495K	﹤0.01%	883
2014 Q3	$523K	Buy	+52,110	New	+$632K	0.01%	729
2014 Q2	–	Sell	-14,762	Closed	-$274K	–	962
2014 Q1	$274K	Buy	+14,762	New	+$296K	﹤0.01%	875

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's PETX Position: Q1 2015 in Review

Sterling Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2015, closing a stake of 12,373 shares — an estimated $220K sold.

Sterling Capital Management first reported a position in PETX in Q1 2014 and held it in 3 quarters. The position peaked at $523K in Q3 2014. 93 funds tracked by Wall St. Rank hold PETX as of Q1 2015.

Sterling Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Sterling Capital Management sold 12,373 Aratana Therapeutics, Inc. shares in Q1 2015, an estimated $220K.
Sterling Capital Management first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
Sterling Capital Management's Aratana Therapeutics, Inc. position peaked at $523K in Q3 2014.
93 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2015.

Based on Sterling Capital Management's 13F filing for Q1 2015, filed 19 May 2015.